Pesquisar
Novo Nordisk A/S
NVOAdicionar à lista de desejos
48.070USD
0.0000.00%
Fechamento 06/26, 16:00（ET）Cotações atrasadas em 15 min
161.68BValor de mercado
11.25P/L TTM
Mais detalhes de Novo Nordisk A/S Empresa
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Informações de Novo Nordisk A/S
Código da empresaNVO
Nome da EmpresaNovo Nordisk A/S
Data de listagemMay 17, 1974
CEODoustdar (Maziar Mike)
Número de funcionários76302
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 17
EndereçoNovo Alle 1
CidadeBAGSVAERD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísDenmark
Código postal2880
Telefone4544448888
Sitehttps://www.novonordisk.com/
Código da empresaNVO
Data de listagemMay 17, 1974
CEODoustdar (Maziar Mike)
Executivos da empresa Novo Nordisk A/S
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Chairman of the Board
Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Ludovic Helfgott
Mr. Ludovic Helfgott
Executive Vice President - Product & Portfolio Strategy
Executive Vice President - Product & Portfolio Strategy
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Chairman of the Board
Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Novo Nordisk A/S?
Os cinco principais acionistas de Novo Nordisk A/S são: Mr. Lars Rebien Soerensen
Quantas instituições possuem ações da Novo Nordisk A/S (NVO)?
Em 2026Q1, 2975 instituições possuíam ações da Novo Nordisk A/S, com valor de mercado aproximado de 332.82M, representando 9.89% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2714627.00.
Qual é a maior fonte de receita da Novo Nordisk A/S?
Em 2026Q1, o segmento de negócios Total GLP-1 gerou a maior receita para Novo Nordisk A/S, totalizando 23.00B e representando 49.25% da receita total.
